OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a
single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for …

Vitamin K plays a role in controlling cell growth. Anti-angiogenic effects of sorafenib lead to
impairment of vitamin K uptake and induction of des-γ-carboxyprothrombin release by …

Background To provide support for combined usage of phosphoinositide 3-kinase (PI3K)
inhibitors or mitogen-activated protein kinase pathway inhibitors together with sorafenib in …

Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced
hepatocellular carcinoma (HCC). Herein, we report the efficacy of sorafenib for extrahepatic …

Background Several intracellular signaling pathways that are deregulated during
hepatocarcinogenesis might constitute potential targets for hepatocellular carcinoma (HCC) …

Purpose Severe adverse events frequently occur in patients treated with sorafenib, whereas
some patients have suboptimal response to sorafenib. We aimed to evaluate the association …

Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of
advanced hepatocellular carcinoma (HCC). However, as the clinical application of sorafenib …

Sorafenib is presently the only effective therapy in advanced hepatocellular carcinoma
(HCC). Because most anticancer drugs act, at least in part, through the generation of …

The multi-kinase inhibitor Sorafenib increases the survival of patients with advanced
hepatocellular carcinoma (HCC). Current data suggest that Sorafenib inhibits cellular …

Mutations affecting the Wnt/β‑catenin pathway have been identified in 26‑40% of
hepatocellular carcinoma (HCC) cases. Aberrant activation of this pathway leads to …